The Box 2.0: Using Smart Technology for Early Diagnosis of Complications After Cardiovascular Surgery

Sponsor
Leiden University Medical Center (Other)
Overall Status
Completed
CT.gov ID
NCT03690492
Collaborator
(none)
730
1
2
32.4
22.5

Study Details

Study Description

Brief Summary

The objective of this study is to determine the effect on quality of care when introducing smart technology in patients who underwent cardiovascular surgery. Patients who consent to take part in the study, receive a box containing two smartphone compatible ECG monitors, an oxygen saturation monitor, a weight scale, a thermometer, an activity tracker and a blood pressure monitor. They will be followed up by replacing one of the outpatient clinic visits by an e-consult, in which a patients does not have to go to the hospital. Instead, he or she will talk with his or her doctor or nurse practitioner via a secured video connection. The primary endpoint of the study will be the diagnosis of atrial fibrillation within 3 months after cardiac surgery.

Condition or Disease Intervention/Treatment Phase
  • Other: The Box 2.0
N/A

Detailed Description

Over the past five years, smartphone compatible detectors of cardiovascular disease parameters have been released on the consumers market. Examples of these include heart rate monitors, ECG monitors, blood pressure monitors, activity trackers and fat percentages monitors. These monitors have often been validated and are CE-marked for use in the European Union within their intended use.

Recent publications implicate that home monitoring with such consumer devices might improve quality of care. A study by Bosworth et al. in patients with hypertension showed that increased monitoring and subsequent treatment led to a better controlled blood pressure in patients who were treated for hypertension. Another study, which is currently being carried out at the LUMC, is investigating whether patients benefit from a smart technology intervention after they had a myocardial infarction. Preliminary (unpublished) results show that clinical outcomes are similar, with higher patient satisfaction. Cost analyses show that there is a cost reduction per patient with smart technology follow-up. Therefore, smart technology could be a useful tool to improve patient monitoring and therefore patient safety.

Patients who are discharged after they underwent cardiovascular surgery are at risk to develop one or more of three most seen late complications: sternal wound infection, cardiac decompensation or rhythm disturbances such as atrial fibrillation. This is not always detected before those patients are discharged.

Currently, patients who underwent cardiovascular surgery return to the outpatient clinic 14 days and three months after discharge. They are seen by a specialist nurse or cardiologist, who will perform a general check-up and inspect the sternal wound. An echocardiogram will be performed before the three-month visit. If there is suspicion for a rhythm disturbance on the outpatient clinic visit, the cardiologist might decide to perform Holter monitoring during 24 hours. As this is a small window of time, not all rhythm disturbances will be diagnosed. Smart technology is hypothesized to increase the chances of diagnosing rhythm disturbances. In the case of sternal wound infection and cardiac decompensation, smart technology may show a declining trend before a patient visits the outpatient clinic, which can lead to early detection and treatment.

A small pilot study by McElroy et all found that after cardiovascular surgery, both the patient as well as the health care team are highly satisfied with added smart technology, due to the ease of use of the technology and platform. There was a main focus on readmission rates, which did not differ between the groups. However the trend shows an increase in diagnosing atrial fibrillation (15,4 vs 29,6%), sternal wound infection or cardiac decompensation were not studied.

To our knowledge, no other study has yet looked into diagnosing late complications after cardiovascular surgery with the help of smart technology. It is hypothesized that smart technology could help diagnose the main three diagnoses mentioned above early on and with that, improve quality of care in patients after cardiovascular surgery. Therefore, in this study, the clinical effectiveness of a smart technology intervention is investigated in patients who have underwent cardiovascular surgery at the department of Thoracic Surgery at Leiden University Medical Center.

Study Design

Study Type:
Interventional
Actual Enrollment :
730 participants
Allocation:
Non-Randomized
Intervention Model:
Parallel Assignment
Masking:
None (Open Label)
Primary Purpose:
Diagnostic
Official Title:
The Box 2.0: Using Smart Technology for Early Diagnosis of Complications After Cardiovascular Surgery
Actual Study Start Date :
Oct 2, 2018
Actual Primary Completion Date :
Mar 15, 2021
Actual Study Completion Date :
Jun 15, 2021

Arms and Interventions

Arm Intervention/Treatment
Experimental: The Box 2.0

Patients will be given a Box, in which they will find a thermometer, blood pressure monitor, activity tracker, weight scale, blood oxygen saturation monitor, a single lead ECG device and a four lead ECG device. Also, they will be followed-up by use of two webcam consultations instead of a normal outpatient clinic visit.

Other: The Box 2.0
Patients in the intervention arm will receive a Box with several devices that is hypothesized to allow for better and earlier detection of complications after cardiac surgery.

No Intervention: Controls

Patients will not receive a Box. They will be followed up by standard care, returning to the outpatient clinic at the same frequency and timing as The Box 2.0 arm.

Outcome Measures

Primary Outcome Measures

  1. Dectection of and time to detection of atrial fibrillation [Until 3 months after surgery]

    Diagnosis of atrial fibrillation and the time it took a subject to reach that outcome, measured in both study arms

Secondary Outcome Measures

  1. Dectection of and time to detection of cardiac decompensation [Until 3 months after surgery]

    Diagnosis of cardiac decompensation and the time it took a subject to reach that outcome, measured in both study arms

  2. Quality of Life (QoL) [3 months after surgery]

    QoL of both study arms, using the EQ-5D-5L (Dutch translation)

  3. Patient satisfaction of care [3 months after surgery]

    Satisfaction in both study arms, using a modified PSQ-18 (Dutch translation)

  4. Overall mortality [3 months after surgery]

    Mortality in both study arms

  5. Major adverse cardiac events [Until 3 months after surgery]

    Either cardiac death, myocardial infarction, cardiac tamponade, TIA or ischaemic stroke

  6. Re-admission to either the cardiology or thoracic surgery ward [Until 3 months after surgery]

    Re-admission in both study arms

  7. Total amount of cardiology related visits to an emergency department until three months after discharge [Until 3 months after surgery]

    ER visits (at the Leids University Medical Center, Alrijne Ziekenhuis or Haaglanden Medisch Centrum) in both arms

  8. Blood pressure control [3 months after surgery]

    BP control in both study arms, both systolic and diastolic

  9. Cost-effectiveness [2 years]

    Cost-effectiveness of the intervention

  10. Detection of and time to detection of sternal wound infection [Until 3 months after surgery]

    Diagnosis of sternal wound infection and the time it took a subject to reach that outcome, measured in both study arms

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Patient undergoes cardiovascular surgery: CABG, valve reconstruction or replacement, aortic root or ascending aortic surgery, or any other cardiothoracic surgery performed by median sternotomy such as atrial or ventricular septal defect closure, Dor or Morrow procedure, cardiac tumor removal and/or surgical treatment of coronary artery anomalies.

  • Patient is able to communicate in English or Dutch

  • Patient has been referred by a cardiologist from the Leiden University Medical Center, Cardiological Center Voorschoten, Alrijne Hospital or Haaglanden Medical Center

Exclusion Criteria:
  • Patient is < 18 years old

  • Patient is pregnant

  • Patient is considered an incapacitated adult

  • Patient is unwilling to sign the informed consent form

  • Patient undergoes emergency thoracic surgery (INTERMACS 1 or 2)

  • Patient has active endocarditis at the time of operation

  • Patient is on mechanical circulatory support before operation

  • Patient has a ventricular septal rupture

  • Patient undergoes extracorporeal membrane oxygenation or ventricular assist device insertion

Contacts and Locations

Locations

Site City State Country Postal Code
1 Leiden University Medical Centre Leiden Zuid Holland Netherlands 2333 ZA

Sponsors and Collaborators

  • Leiden University Medical Center

Investigators

None specified.

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
RoderickTreskes, Principal Investigator, Leiden University Medical Center
ClinicalTrials.gov Identifier:
NCT03690492
Other Study ID Numbers:
  • NL65959.058.18
First Posted:
Oct 1, 2018
Last Update Posted:
Sep 8, 2021
Last Verified:
Sep 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Product Manufactured in and Exported from the U.S.:
No

Study Results

No Results Posted as of Sep 8, 2021